Monday, November 7, 2022
9:21 AM EST – Oncolytics Biotech Inc : Today announced recent operational highlights and financial results for the third quarter ended September 30, 2022. Operational highlights include; Clinical interim data reported earlier today from GOBLET trial’s pancreatic cancer cohort show an objective response rate nearly triple the average ORR seen in relevant historical control trials. $32.4 million in cash and cash equivalents as of September 30, 2022 provides projected runway through key milestones to the end of 2023. Oncolytics Biotech Inc (T.ONC) shares were -$0.03 at 1.7.
Stocks in Play: Oncolytics Biotech Inc, Mon, 07 Nov 2022 09:27:06 EST